Literature DB >> 30732460

Predictors of allodynia in persons with migraine: Results from the Migraine in America Symptoms and Treatment (MAST) study.

David W Dodick1, Michael L Reed2, Kristina M Fanning2, Sagar Munjal3, Aftab Alam3, Dawn C Buse4, Todd J Schwedt1, Richard B Lipton4.   

Abstract

BACKGROUND: Cutaneous allodynia is a common clinical feature of migraine that has been associated with reduced efficacy of acute migraine treatments and an increased risk of disease progression.
OBJECTIVE: Identify factors associated with allodynia in a sample of adults with migraine.
METHODS: An online survey panel was used to identify adults with migraine who averaged at least 1 monthly headache day over the previous 3 months. Data on sociodemographics, headache frequency, headache pain intensity, migraine symptom severity, medication use, depression and anxiety, and cutaneous allodynia (via the Allodynia Symptom Checklist) were obtained. Binary logistic modeling predicted the presence of allodynia. Odds ratios and 95% confidence intervals (CI) were calculated.
RESULTS: In total, 15,133 individuals with migraine met the eligibility criteria. Mean age was 43.1 years, 73.0% were female, and 81.0% were Caucasian. Allodynia was present in 39.9%. The fully adjusted model, controlling for sociodemographics and headache features, demonstrated that allodynia was significantly associated with a higher migraine symptom severity score (odds ratio 1.17, confidence interval 1.15, 1.19) and more severe pain intensity (odds ratio 1.11, confidence interval 1.08, 1.14); probable depression and/or anxiety (odds ratio 1.83, confidence interval 1.67, 2.00); and overuse of acute medication (odds ratio 1.23, confidence interval 1.09, 1.38). A higher number of monthly headache days increased the likelihood of allodynia, but the effect was attenuated in the fully adjusted model.
CONCLUSION: In a representative sample of US adults with migraine, there were significant associations between allodynia and headache frequency and intensity, anxiety and/or depression, symptom severity, and acute medication overuse.

Entities:  

Keywords:  Migraine; acute medication overuse; anxiety; cutaneous allodynia; depression; epidemiology; headache frequency; headache pain intensity; migraine symptom severity

Mesh:

Year:  2019        PMID: 30732460     DOI: 10.1177/0333102418825346

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  11 in total

1.  Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks.

Authors:  Stewart J Tepper; Raghavendra Vasudeva; John H Krege; Suchitrita S Rathmann; Erin Doty; Bert B Vargas; Delphine Magis; Mika Komori
Journal:  Headache       Date:  2020-07-07       Impact factor: 5.887

2.  TRPM8 genetic variant is associated with chronic migraine and allodynia.

Authors:  Yu-Hsiang Ling; Shih-Pin Chen; Cathy Shen-Jang Fann; Shuu-Jiun Wang; Yen-Feng Wang
Journal:  J Headache Pain       Date:  2019-12-16       Impact factor: 7.277

3.  Prevalence and characteristics of cutaneous allodynia in probable migraine.

Authors:  Seung Min Han; Kyung Min Kim; Soo-Jin Cho; Kwang Ik Yang; Daeyoung Kim; Chang-Ho Yun; Min Kyung Chu
Journal:  Sci Rep       Date:  2021-01-28       Impact factor: 4.379

4.  Can Allodynia Predict Headache Related to Personal Protective Equipment for the Prevention of COVID-19?

Authors:  Karen Dos Santos Ferreira; Ana Miriam Velly
Journal:  J Med Cases       Date:  2021-03-05

Review 5.  Cutaneous Allodynia in Migraine: A Narrative Review.

Authors:  Ane Mínguez-Olaondo; Sonia Quintas; Noemí Morollón Sánchez-Mateos; Alba López-Bravo; Marta Vila-Pueyo; Vesselina Grozeva; Robert Belvís; Sonia Santos-Lasaosa; Pablo Irimia
Journal:  Front Neurol       Date:  2022-01-21       Impact factor: 4.003

6.  Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).

Authors:  Piero Barbanti; Gabriella Egeo; Cinzia Aurilia; Florindo d'Onofrio; Maria Albanese; Ilaria Cetta; Paola Di Fiore; Maurizio Zucco; Massimo Filippi; Francesco Bono; Claudia Altamura; Stefania Proietti; Stefano Bonassi; Fabrizio Vernieri
Journal:  J Headache Pain       Date:  2022-04-09       Impact factor: 7.277

7.  The Scratch Collapse Test for Diagnosis and Treatment of Trigger Sites for Migraine Surgery.

Authors:  Harvey Chim
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-02-22

8.  Preclinical assessment of onabotulinumtoxinA for the treatment of mild traumatic brain injury-related acute and persistent post-traumatic headache.

Authors:  Edita Navratilova; Janice Oyarzo; Trent Anderson; Ron S Broide; Sudhakar R Subramaniam; Edwin J Vazquez-Cintron; Mitchell F Brin; Todd J Schwedt; David W Dodick; Frank Porreca
Journal:  Cephalalgia       Date:  2022-05-11       Impact factor: 6.075

9.  Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study.

Authors:  Sagar Munjal; Preeti Singh; Michael L Reed; Kristina Fanning; Todd J Schwedt; David W Dodick; Dawn C Buse; Richard B Lipton
Journal:  Headache       Date:  2019-12-14       Impact factor: 5.887

10.  Excess abdominal fat is associated with cutaneous allodynia in individuals with migraine: a prospective cohort study.

Authors:  Ane Mínguez-Olaondo; Iván Martínez-Valbuena; Sonia Romero; Gema Frühbeck; María Rosario Luquin; Eduardo Martínez-Vila; Pablo Irimia
Journal:  J Headache Pain       Date:  2020-02-04       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.